Archives
A-769662: Potent Small Molecule AMPK Activator for Metabo...
A-769662: Potent Small Molecule AMPK Activator for Metabolic Research
Executive Summary: A-769662 is a reversible, allosteric small molecule activator of AMP-activated protein kinase (AMPK), with an in vitro EC50 of 0.8–0.116 μM, demonstrating selective AMPK activation and downstream substrate phosphorylation in multiple cell types (Park et al., 2023). In primary rat hepatocytes, A-769662 inhibits fatty acid synthesis with an IC50 of 3.2 μM and increases acetyl-CoA carboxylase (ACC) phosphorylation. In vivo, oral administration in mice (30 mg/kg) reduces plasma glucose by 40% and suppresses hepatic gluconeogenic enzyme expression. Notably, A-769662 also inhibits the 26S proteasome independently of AMPK activation. Recent studies clarify that AMPK activation by A-769662 can suppress autophagy via inhibition of ULK1, challenging previous models of AMPK-induced autophagy (Park et al., 2023).
Biological Rationale
AMPK is a conserved serine/threonine kinase complex critical for cellular energy homeostasis. It is composed of α (catalytic), β, and γ (regulatory) subunits, and acts as a sensor of cellular energy status by monitoring the AMP:ATP ratio (Park et al., 2023). Upon energy stress, such as glucose deprivation or mitochondrial dysfunction, AMPK is activated. Activation leads to inhibition of ATP-consuming anabolic pathways (e.g., cholesterol synthesis, fatty acid synthesis, gluconeogenesis), and stimulation of ATP-generating catabolic processes (e.g., fatty acid oxidation, glycolysis). This makes AMPK a central node in metabolic disease research, including type 2 diabetes and metabolic syndrome models.
Mechanism of Action of A-769662
A-769662 (4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile; MW 360.39) is a thienopyridone compound developed as a potent and reversible allosteric activator of AMPK (APExBIO). It binds at a site distinct from the AMP-binding pocket, resulting in conformational changes that promote AMPK activation. A-769662 inhibits dephosphorylation of the critical Thr-172 residue on the AMPK α-subunit, stabilizing the active kinase conformation. The compound's selectivity for AMPK is demonstrated by its low EC50 (0.8–0.116 μM, assay-dependent) and by its ability to increase phosphorylation of ACC, a direct substrate of AMPK. Additionally, A-769662 inhibits the 26S proteasome through an AMPK-independent mechanism, resulting in G1 cell cycle arrest without affecting core 20S proteolytic activity.
Evidence & Benchmarks
- A-769662 activates AMPK in vitro with an EC50 of 0.8–0.116 μM depending on assay conditions (APExBIO).
- In rat hepatocytes, A-769662 inhibits fatty acid synthesis with an IC50 of 3.2 μM and increases ACC phosphorylation in a dose-dependent manner (APExBIO).
- Oral dosing in mice (30 mg/kg) reduces plasma glucose by 40% and downregulates hepatic gluconeogenic enzymes (FAS, G6Pase, PEPCK), confirming metabolic efficacy in vivo (APExBIO).
- A-769662 suppresses autophagosome formation in cell models, indicating that AMPK activation can inhibit, not promote, autophagy via ULK1 inhibition (Park et al., 2023).
- Inhibition of 26S proteasome activity by A-769662 occurs independently of AMPK, distinguishing it from canonical AMPK activators (APExBIO).
- For additional mechanistic details and comparative analysis, see "A-769662: Unraveling AMPK Activation and Metabolic Circuitry", which provides expanded discussion of metabolic circuit modulation; the current article updates recent discoveries regarding autophagy suppression and benchmark parameters.
Applications, Limits & Misconceptions
A-769662 is widely used in research on energy metabolism regulation, fatty acid synthesis inhibition, and proteasome function. It is a reference tool for dissecting the AMPK signaling pathway and for modeling metabolic diseases such as type 2 diabetes and metabolic syndrome (see also for peer-reviewed boundaries; this article clarifies AMPK-autophagy relationships and proteasome effects).
Common Pitfalls or Misconceptions
- Not a universal autophagy inducer: While previously thought to promote autophagy, A-769662-activated AMPK can suppress autophagy by inhibiting ULK1 in energy-stressed cells (Park et al., 2023).
- AMPK-independent proteasome inhibition: A-769662 inhibits the 26S proteasome independently of AMPK activation, which may confound experiments aimed solely at AMPK pathway interrogation.
- Solubility limitations: The compound is soluble in DMSO (>18 mg/mL) but insoluble in water and ethanol, restricting some experimental formats.
- Storage sensitivity: A-769662 should be stored at -20°C; solutions are recommended for short-term use only (APExBIO).
- Cell-type specificity: Quantitative efficacy (e.g., EC50, IC50) can vary with cell line, assay, and species (see also; this article provides updated in vivo benchmarks and mechanistic clarification).
Workflow Integration & Parameters
A-769662 (SKU: A3963) is supplied by APExBIO (see product page). Recommended working concentrations range from 0.5 μM to 10 μM for cell-based assays. For in vivo rodent studies, oral doses of 30 mg/kg have yielded robust metabolic effects. Solutions should be freshly prepared in DMSO, stored at -20°C, and used within a short time frame for maximal activity. The molecule is suited for protocols investigating AMPK signaling, fatty acid synthesis inhibition, gluconeogenesis suppression, and 26S proteasome function. Researchers should validate endpoints (e.g., ACC phosphorylation, glucose output, proteasome activity) and remain aware of AMPK-independent actions. For further workflow insights and peer-reviewed protocols, consult this article, which this dossier extends with updated autophagy and proteasome data.
Conclusion & Outlook
A-769662 remains a benchmark small molecule AMPK activator with proven selectivity and efficacy in both in vitro and in vivo models. Its dual action—activating AMPK and inhibiting the 26S proteasome—enables sophisticated interrogation of energy metabolism, fatty acid synthesis, and protein turnover. Recent mechanistic clarification that AMPK activation by A-769662 can suppress autophagy via ULK1 inhibition challenges longstanding assumptions and guides more precise experimental design. For robust AMPK pathway research in metabolic disease and energy homeostasis, A-769662 (A3963) from APExBIO represents a validated, well-characterized tool.